These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27660487)

  • 1. OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.
    Fudin J; Raouf M; Wegrzyn EL
    J Pain Res; 2016; 9():609-12. PubMed ID: 27660487
    [No Abstract]   [Full Text] [Related]  

  • 2. OxyContin abuse and diversion and efforts to address the problem: highlights of a government report.
    Government Accounting Office
    J Pain Palliat Care Pharmacother; 2004; 18(3):109-13. PubMed ID: 15364638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OxyContin abuse and overdose.
    Aquina CT; Marques-Baptista A; Bridgeman P; Merlin MA
    Postgrad Med; 2009 Mar; 121(2):163-7. PubMed ID: 19332974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A profile of OxyContin addiction.
    Hays LR
    J Addict Dis; 2004; 23(4):1-9. PubMed ID: 15339710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An exploratory study of OxyContin use among individuals with substance use disorders.
    Levy MS
    J Psychoactive Drugs; 2007 Sep; 39(3):271-6. PubMed ID: 18159780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-medical use of OxyContin Tablets in the United States.
    Sees KL; Di Marino ME; Ruediger NK; Sweeney CT; Shiffman S
    J Pain Palliat Care Pharmacother; 2005; 19(2):13-23. PubMed ID: 16061457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG; Coplan PM
    Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013.
    Jones CM; Muhuri PK; Lurie PG
    Clin J Pain; 2017 May; 33(5):452-461. PubMed ID: 27513641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
    Vosburg SK; Haynes C; Besharat A; Green JL
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
    Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
    Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
    J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations of cancer pain degree with levels of β-EP, CGRP and PGE2 and the effects of oxycontin on them.
    Chong D; Shao L; Yang Y; Wang R; Yang C; Zhang B
    J BUON; 2018; 23(5):1552-1557. PubMed ID: 30570885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.
    Hays L; Kirsh KL; Passik SD
    J Natl Compr Canc Netw; 2003 Jul; 1(3):423-8. PubMed ID: 19761073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The OxyContin crisis: problematisation and responsibilisation strategies in addiction, pain, and general medicine journals.
    Whelan E; Asbridge M
    Int J Drug Policy; 2013 Sep; 24(5):402-11. PubMed ID: 23452867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OxyContin in Ontario: the multiple materialities of prescription painkillers.
    King S
    Int J Drug Policy; 2014 May; 25(3):486-93. PubMed ID: 24612641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose controlled-release oxycodone in hospice care.
    Bercovitch M; Adunsky A
    J Pain Palliat Care Pharmacother; 2006; 20(4):33-9. PubMed ID: 17182504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions.
    Cone EJ; Fant RV; Rohay JM; Caplan YH; Ballina M; Reder RF; Haddox JD
    J Anal Toxicol; 2004 Oct; 28(7):616-24. PubMed ID: 15516322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.